1. Home
  2. ONC vs DTE Comparison

ONC vs DTE Comparison

Compare ONC & DTE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ONC
  • DTE
  • Stock Information
  • Founded
  • ONC 2010
  • DTE 1903
  • Country
  • ONC Switzerland
  • DTE United States
  • Employees
  • ONC N/A
  • DTE N/A
  • Industry
  • ONC Biotechnology: Pharmaceutical Preparations
  • DTE Electric Utilities: Central
  • Sector
  • ONC Health Care
  • DTE Utilities
  • Exchange
  • ONC Nasdaq
  • DTE Nasdaq
  • Market Cap
  • ONC 26.9B
  • DTE 28.2B
  • IPO Year
  • ONC N/A
  • DTE N/A
  • Fundamental
  • Price
  • ONC $247.08
  • DTE $132.36
  • Analyst Decision
  • ONC Strong Buy
  • DTE Buy
  • Analyst Count
  • ONC 7
  • DTE 14
  • Target Price
  • ONC $326.43
  • DTE $140.00
  • AVG Volume (30 Days)
  • ONC 314.8K
  • DTE 1.3M
  • Earning Date
  • ONC 08-06-2025
  • DTE 07-24-2025
  • Dividend Yield
  • ONC N/A
  • DTE 3.29%
  • EPS Growth
  • ONC N/A
  • DTE 20.97
  • EPS
  • ONC N/A
  • DTE 7.39
  • Revenue
  • ONC $4,175,868,000.00
  • DTE $13,657,000,000.00
  • Revenue This Year
  • ONC $869.15
  • DTE $8.24
  • Revenue Next Year
  • ONC $19.07
  • DTE $2.69
  • P/E Ratio
  • ONC N/A
  • DTE $17.92
  • Revenue Growth
  • ONC 51.16
  • DTE 11.89
  • 52 Week Low
  • ONC $141.31
  • DTE $108.40
  • 52 Week High
  • ONC $287.88
  • DTE $140.39
  • Technical
  • Relative Strength Index (RSI)
  • ONC N/A
  • DTE 42.12
  • Support Level
  • ONC N/A
  • DTE $131.09
  • Resistance Level
  • ONC N/A
  • DTE $136.26
  • Average True Range (ATR)
  • ONC 0.00
  • DTE 1.74
  • MACD
  • ONC 0.00
  • DTE -0.35
  • Stochastic Oscillator
  • ONC 0.00
  • DTE 22.55

About ONC BeiGene Ltd. American Depositary Shares

Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeiGene is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeiGene runs global clinical trials with its own team. As of 2024, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 60% of BeiGene's revenue.

About DTE DTE Energy Company

DTE Energy owns two regulated utilities in Michigan that contribute 90% of earnings. DTE Electric serves approximately 2.3 million customers in southeastern Michigan, including Detroit. DTE Gas serves 1.3 million customers throughout the state. In addition, DTE has nonutility businesses and investments including energy marketing and trading, renewable natural gas facilities, and on-site industrial energy projects.

Share on Social Networks: